Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Mark Davis to moderate 'Novel approaches to drug delivery in cancer' session at the AACR meeting

Founder of Insert Therapeutics and Calando Pharmaceuticals Sheds Light on Nanoparticle Therapeutics for Cancer

Mark Davis to moderate 'Novel approaches to drug delivery in cancer' session at the AACR meeting

PASADENA, CA, | Posted on April 12th, 2007

Arrowhead Research Corporation (NASDAQ:ARWR) announced today that Mark Davis, Ph.D, the founder of two of its majority-owned subsidiary companies Insert Therapeutics, Inc. and Calando Pharmaceuticals, Inc. will moderate and speak at the "Novel Approaches to Drug Delivery in Cancer" session during the 2007 American Association for Cancer Research (AACR) Annual Meeting on Saturday, April 14, 2007. This session will also feature Dr. Dong Shin (Winship Cancer Center), Dr. Peter Senter (Seattle Genetics) and Dr. Anna Wu (UCLA).

In his role as a speaker, Dr. Davis will deliver a presentation
titled "Fundamental Issues in Nanoparticle Therapeutics for Cancer"
in which he will review such critical factors as control of size and
surface charge of nanoparticles. In addition, he will explain the
features of nanoparticles that make them particularly interesting for
cancer therapeutics, such as multivalent targeting to cell surface
receptors. Dr. Davis will also describe a nanoparticle experimental
therapeutic that is in early clinical trials.

"The session is predicated on the increasing necessity to overcome
existing limitations in drug delivery systems for cancer," said Dr.
Davis. "We aim to summarize some of the most exciting new
technologies in the pre-clinical and clinical settings with emphasis
on their role in providing better approaches to drug delivery."

In addition to being the Founder of Insert Therapeutics and Calando
Pharmaceuticals, Dr. Davis is the Warren and Katharine Schlinger
Professor of Chemical Engineering at the California Institute of
Technology. He is a member of the National Academy of Engineering and
the National Academy of Sciences, and a recipient of numerous awards
including the prestigious Alan T. Waterman Award, given by the
National Science Foundation annually to only one scientist in the
United States across all disciplines. Dr. Davis was the first
engineer to win this award for his work in rationally designed
materials. Dr. Davis earned his B.S., M.S. and Ph.D. degrees in
Chemical Engineering and holds over 50 patents, has published more
than 350 papers and has presented over 500 seminars throughout the


About Arrowhead Research Corporation
Arrowhead Research Corporation ( ) is a
publicly-traded nanotechnology company commercializing new
technologies in the areas of life sciences, electronics, and energy.
Arrowhead is building value for shareholders through the progress of
majority owned subsidiaries founded on nanotechnologies originally
developed at universities. The company works closely with
universities to source early stage deals and to generate rights to
intellectual property covering promising new nanotechnologies.
Currently, Arrowhead has four subsidiaries commercializing nanotech
products and applications, including anti-cancer drugs, RNAi
therapeutics, carbon-based electronics and compound semiconductor

About Insert Therapeutics, Inc.

Insert Therapeutics, Inc., a majority-owned subsidiary of Arrowhead
Research Corporation (NASDAQ:ARWR), is using its proprietary,
nano-engineered, polymeric delivery system, Cyclosert(TM), to design,
develop and commercialize drug-delivery-enhanced small-molecule
therapeutics and nucleic acids. Cyclosert uses cyclodextrins as
building blocks to create an entirely new class of biocompatible
materials - linear cyclodextrin-containing polymers that are nontoxic
and nonimmunogenic at therapeutic doses. Insert is pursuing this goal
through its internal research and development and also through
collaborations and partnerships with pharmaceutical and biotechnology

About Calando Pharmaceuticals Inc.

Calando Pharmaceuticals Inc., a majority owned subsidiary of
Arrowhead Research Corporation (NASDAQ: ARWR), is using its
proprietary technologies in targeted polymeric delivery systems and
siRNA design to design and create new, targeted siRNA therapeutics.
The company is pursuing this goal through its internal research and
development and also through collaborations and partnerships with
pharmaceutical and biotechnology companies.

Safe Harbor Statement under the Private Securities Litigation Reform
Act of 1995

This news release contains forward-looking statements within the
meaning ofthe "safe harbor" provisions of the Private Securities
Litigation Reform Actof 1995. These statements are based upon our
current expectations and speak onlyas of the date hereof. Our actual
results may differ materially and adversely from those expressed in
any forward-looking statements as a result of various factorsand
uncertainties, including the recent economic slowdown affecting
technology companies, the future success of our scientific studies,
our ability to successfully develop products, rapid technological
change in our markets, changes in demand for our future products,
legislative, regulatory and competitive developments and general
economic conditions. Our Annual Report on Form 10-K and 10-K/A,
recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A,
recent Current Reports on Forms 8-K and 8-K/A, our Registration
Statement on Form S-3, and other SEC filingsdiscuss some of the
important risk factors that may affect our business, results of
operations and financial condition. We undertake no obligation to
revise or update publicly any forward-looking statements for any

For more information, please click here

Robert Marshall
Insert Therapeutics
Telephone: 626.683.7200

Virginia Dadey
Arrowhead Research
Telephone: 212.541.3707

Copyright © Arrowhead Research Corporation

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press


New nanomedicine approach aims to improve HIV drug therapies October 24th, 2016

Nanosciences: Genes on the rack October 21st, 2016

Nanoparticle vaccinates mice against dengue fever October 21st, 2016

Tiny gold particles could be the key to developing a treatment for pancreatic cancer October 19th, 2016


Precise quantum cloning: possible pathway to secure communication: Physicists create best ever quantum clones October 26th, 2016

The quantum sniffer dog: A laser and detector in 1: A microscopic sensor has been developed at TU Wien, which can be used to identify different gases simultaneously October 25th, 2016

Hybrid nanostructures hold hydrogen well: Rice University scientists say boron nitride-graphene hybrid may be right for next-gen green cars October 25th, 2016

New method increases energy density in lithium batteries: Novel technique may lead to longer battery life in portable electronics and electrical vehicles October 24th, 2016


KaSAM-2016: International Conference on Material Sciences has successfully concluded in Pokhara of Western Nepal October 24th, 2016

Leti Scientists Participating in Sessions on Med Tech, Automotive Technologies, MEMS, Si-photonics and Lithography at SEMICON Europa: Teams also Will Demonstrate Technology Advances in Telecom, Data Fusion, Energy, Silicon Photonics and 3D Integration October 18th, 2016

The University of Applied Sciences in Upper Austria uses Deben tensile stages as an integral part of their computed tomography research and testing facility October 18th, 2016

Pokhara (Nepal) all set to host KaSAM-2016: An International Scientific Meeting on Advanced Materials October 15th, 2016

The latest news from around the world, FREE

  Premium Products
Only the news you want to read!
 Learn More
University Technology Transfer & Patents
 Learn More
Full-service, expert consulting
 Learn More

Nanotechnology Now Featured Books


The Hunger Project